Glyburide
Glyburide is a sulfonylurea (a type of diabetes pill) used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 44 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Glyburide is a sulfonylurea for type 2 diabetes that prompts the pancreas to release more insulin, so it works only while those insulin-making cells still function; on the market since about 1984 and available as a generic, it is a familiar older standby, usually added to metformin rather than chosen first. Most people tolerate it well, and the side effects they notice are mostly mild stomach complaints like nausea, heartburn or upper-stomach fullness. The real risk is low blood sugar, especially after a skipped meal or in older adults and anyone with kidney problems; learn its warning signs and treat confusion or passing out as an emergency.
Clinical pearls
- Take it with breakfast or your first main meal, so the insulin boost it triggers lines up with food.
- If you take colesevelam for cholesterol, take glyburide at least 4 hours before it, or less of it gets absorbed.
- Bosentan must never be combined with it, and ciprofloxacin, oral miconazole or NSAID pain relievers can drive blood sugar dangerously low.
- Tell your prescriber about any sulfa drug allergy, because people allergic to sulfonamides may react to glyburide too.
Patient information guide A plain-language walkthrough of Glyburide, written from its FDA label.
What Glyburide is used for
▾
Glyburide is used for one main purpose:
- Glyburide tablets, along with diet and exercise, improve blood sugar control in adults with type 2 diabetes.
How Glyburide works
▾
Glyburide mainly works by prompting the pancreas to release insulin. This depends on having working beta cells (the insulin-making cells) in the pancreas.
How it keeps lowering blood sugar over the long term isn't clear. Some people respond less well over time. Some who stopped responding to other sulfonylureas may still respond to glyburide.
Glyburide dosage
▾
Glyburide is taken by mouth as a tablet, usually with breakfast or the first main meal. Many people take it once a day. Some take it twice a day.
- Your prescriber adjusts the dose slowly based on blood sugar results.
- Take it at least 4 hours before colesevelam if you use both.
- It can be combined with metformin when metformin alone isn't enough.
Follow your prescriber's directions and the pharmacy label.
Dosing details from the FDA-approved label
From the Glyburide prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Usual starting dose
- 2.5 to 5 mg daily, administered with breakfast or the first main meal
- Patients who may be more sensitive to hypoglycemic drugs should be started at 1.25 mg daily
- Transfer from other oral antidiabetic therapy
- Initial daily dose should be 2.5 to 5 mg
- Transfer conservatively; no transition period or priming dose when transferring from agents other than chlorpropamide; when transferring from chlorpropamide, take particular care during the first two weeks
- Patients receiving insulin, less than 20 units daily
- Substitution of glyburide tablets 2.5 to 5 mg as a single daily dose may be tried
- Patients receiving insulin, between 20 and 40 units daily
- Placed directly on glyburide tablets 5 mg daily as a single dose
- Patients receiving insulin, more than 40 units daily
- Insulin dosage is decreased by 50% and glyburide tablets 5 mg daily is started
- Progressive withdrawal of insulin and increase of glyburide tablets in increments of 1.25 to 2.5 mg every 2 to 10 days
- A transition period is required; hypoglycemia may occur during conversion
- Maintenance dose (titration)
- Usual maintenance dose is 1.25 to 20 mg daily, as a single dose or in divided doses
- Increases in increments of no more than 2.5 mg at weekly intervals based on blood glucose response
- Maximum: Daily doses of more than 20 mg are not recommended
- Once-a-day therapy is usually satisfactory; some patients, particularly those receiving more than 10 mg daily, may respond better to twice-a-day dosage
- Concomitant glyburide and metformin therapy
- Add glyburide gradually to the regimen of patients who have not responded to the maximum dose of metformin monotherapy after four weeks
- Adjust the dose of each drug
- Risk of hypoglycemia continues and may be increased
- Patients receiving colesevelam
- Glyburide tablets should be administered at least 4 hours prior to colesevelam
- Elderly, debilitated or malnourished patients, and patients with impaired renal or hepatic function
- Initial and maintenance dosing should be conservative
- To avoid hypoglycemic reactions
- Pregnancy and pediatric patients
- Not recommended for use
Read the label’s full dosing text
DOSAGE AND ADMINISTRATION There is no fixed dosage regimen for the management of diabetes mellitus with glyburide tablets. In addition to the usual monitoring of urinary glucose, the patient's blood glucose must also be monitored periodically to determine the minimum effective dose for the patient; to detect primary failure, i.e. , inadequate lowering of blood glucose at the maximum recommended dose of medication; and to detect secondary failure, i.e. , loss of adequate blood glucose lowering response after an initial period of effectiveness. Glycosylated hemoglobin levels may also be of value in monitoring the patient's response to therapy. Short-term administration of glyburide tablets may be sufficient during periods of transient loss of control in patients usually controlled well on diet. Usual Starting Dose The usual starting dose of glyburide tablets is 2.5 to 5 mg daily, administered with breakfast or the first main meal. Those patients who may be more sensitive to hypoglycemic drugs should be started at 1.25 mg daily. (See PRECAUTIONS section for patients at increased risk.) Failure to follow an appropriate dosage regimen may precipitate hypoglycemia. Patients who do not adhere to their prescribed dietary and drug regimen are more prone to exhibit unsatisfactory response to therapy. Transfer From Other Hypoglycemic Therapy Patients Receiving Other Oral Antidiabetic Therapy Transfer of patients from other oral antidiabetic regimens to glyburide tablets should be done conservatively and the initial daily dose should be 2.5 to 5 mg. When transferring patients from oral hypoglycemic agents other than chlorpropamide to glyburide tablets, no transition period and no initial or priming dose are necessary. When transferring patients from chlorpropamide, particular care should be exercised during the first two weeks because the prolonged retention of chlorpropamide in the body and subsequent overlapping drug effects may provoke hypoglycemia. Patients Receiving Insulin Some Type II diabetic patients being treated with insulin may respond satisfactorily to glyburide tablets. If the insulin dose is less than 20 units daily, substitution of glyburide tablets 2.5 to 5 mg as a single daily dose may be tried. If the insulin dose is between 20 and 40 units daily, the patient may be placed directly on glyburide tablets 5 mg daily as a single dose.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Glyburide side effects
▾
The most common side effects are stomach-related, and they often ease if the dose is lowered.
Common side effects
- Nausea
- Fullness in the upper stomach
- Heartburn
- Itching, redness, hives or skin rash
- Low blood sugar (hypoglycemia)
- Blurred vision linked to changing blood sugar levels
When to get medical help
- Signs of severe low blood sugar, such as confusion, seizure or passing out: this is an emergency and needs immediate medical care
- Yellow skin or eyes, or signs of liver problems
- Skin reactions that don't go away
- Swelling of the face or throat, joint or muscle pain, or other signs of a serious allergic reaction
- Unusual bruising, bleeding, frequent infections or severe tiredness, which can signal blood cell problems
- Skin that becomes very sensitive to sunlight
Glyburide warnings and precautions
▾
- Low blood sugar is the biggest risk, especially if you skip meals or don't follow your dosing plan.
- Diabetes pills in this class have been linked to a higher risk of death from heart and blood vessel problems.
- People allergic to sulfa drugs may react to glyburide.
- Rare liver, blood cell and low sodium problems have been reported.
- Your blood sugar needs regular checking to confirm the drug is working.
Glyburide interactions
▾
Many medicines can push your blood sugar too low or too high while you take glyburide.
- Bosentan: must not be combined; raises liver enzyme risk.
- NSAIDs, salicylates, sulfonamides, chloramphenicol, probenecid, warfarin-type drugs, MAO inhibitors, beta blockers: can increase low blood sugar risk.
- Ciprofloxacin and oral miconazole: can cause low blood sugar, sometimes severe.
- Diuretics, corticosteroids, thyroid products, estrogens, birth control pills, phenytoin, niacin and others: can raise blood sugar and weaken control.
- Colesevelam: reduces glyburide absorption; take glyburide at least 4 hours earlier.
- Topiramate: lowers glyburide levels somewhat.
Interactions listed in the FDA-approved label
From the Glyburide prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Non-steroidal anti-inflammatory agents and other highly protein-bound drugs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, beta adrenergic blocking agents: The hypoglycemic action of sulfonylureas may be potentiated. Observe the patient closely for hypoglycemia when added, and for loss of control when withdrawn.
- Bosentan: An increased risk of liver enzyme elevations was observed with concomitant use. Concomitant administration is contraindicated.
- Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, isoniazid: These drugs tend to produce hyperglycemia and may lead to loss of control. Observe closely for loss of control when added, and for hypoglycemia when withdrawn.
- Ciprofloxacin: A possible interaction has been reported, resulting in potentiation of the hypoglycemic action of glyburide; the mechanism is not known.
- Miconazole (oral): A potential interaction with oral hypoglycemic agents leading to severe hypoglycemia has been reported. It is not known whether this occurs with intravenous, topical or vaginal miconazole.
- Metformin: In a single-dose study, decreases in glyburide AUC and Cmax were observed but were highly variable; clinical significance is uncertain. Glyburide did not change metformin pharmacokinetics or pharmacodynamics.
- Colesevelam: Coadministration reduced glyburide AUC and Cmax by 32% and 47%; reductions were 20% and 15% when glyburide was given 1 hour before, and not significantly changed (-7% and 4%) when given 4 hours before colesevelam. Administer glyburide at least 4 hours prior to colesevelam.
- Topiramate: Topiramate 150 mg/day decreased glyburide (5 mg/day) Cmax by 22% and AUC24 by 25%; metabolites M1 and M2 AUC reduced by 13% and 15% and Cmax by 18% and 25%; topiramate pharmacokinetics were unaffected.
Read the label’s full interactions text
Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glyburide tablets, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism for this interaction is not known. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known. Metformin In a single-dose interaction study in NIDDM subjects, decreases in glyburide AUC and C max were observed, but were highly variable.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Glyburide
▾
- Do not use if allergic to glyburide, or if you have type 1 diabetes or diabetic ketoacidosis.
- Do not use with bosentan.
- Tell your prescriber about any sulfa allergy.
- Not recommended in pregnancy or for children.
- Older, frail or malnourished people, and those with kidney or liver problems, need conservative dosing.
Glyburide overdose
▾
Too much glyburide can cause low blood sugar. Mild symptoms are treated with oral glucose and changes to the dose or meals. Severe cases with coma or seizure are emergencies needing immediate hospital care, and monitoring continues for 24 to 48 hours because low blood sugar can return.
What Glyburide does in the body
▾
Glyburide lowers blood sugar by stimulating insulin release from the pancreas. Its blood sugar-lowering effect lasts about 24 hours after a morning dose. It also causes a mild increase in urine output.
How your body processes Glyburide
▾
Glyburide is absorbed within an hour and peaks in about 2 to 3 hours. Its half-life is about 4 hours. The body breaks it down into weakly active metabolites. These leave the body about equally through bile and urine.
How to store Glyburide
▾
Store at 20º to 25ºC (68º to 77ºF); excursions permitted between 15º to 30ºC (59º to 86ºF) Dispensed in well closed containers with safety closures.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Glyburide
331 supplements and herbal products have documented interactions with Glyburide in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 7
- Moderate · 279
- Minor · 45
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Nutrient depletion considerations
Glyburide has been associated with lower levels of 1 nutrient in the clinical literature. This does not mean a deficiency will occur — it means these may be worth discussing with your pharmacist or healthcare provider, especially with long-term use.
Educational information from a licensed clinical database (Natural Medicines) — not medical advice. Do not start or stop medications or supplements without professional guidance.
Glyburide: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Glyburide — the kind of thing our pharmacy team would talk through with you at the counter.
What is glyburide for?
▾
How and when should I take it?
▾
What is the biggest side effect to watch for?
▾
Are there medicines I should avoid with it?
▾
Can I take it if I'm pregnant or if my child has diabetes?
▾
What if I take a cholesterol drug like colesevelam?
▾
Is Glyburide available over the counter?
▾
When was Glyburide first available?
▾
Who makes Glyburide?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Glyburide on HelloPharmacist
Glyburide forms and strengths (how it comes)
Glyburide is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Glyburide inactive ingredients by manufacturer.
Tablet
How this form is used
- Glyburide tablets are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Glyburide tablets are usually started with breakfast or the first main meal.
- Glyburide tablets are usually taken once a day, though some people may do better with twice-daily dosing.
- Glyburide tablets should be taken at least 4 hours before colesevelam if both are used.
Glyburide on the U.S. market: products, makers and brands
How Glyburide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
15 companies list 55 Glyburide product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 1984. Brand names on the directory include DiaBeta, Glynase, Micronase; the rest are generics.
Also listed with the FDA, not a patient dose form: Powder (7) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Glyburide is used (Medicaid data)
A general measure of how commonly Glyburide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Glyburide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Glyburide prescribed? Of the 1,601 medications we measure, Glyburide ranks #530 by Medicaid prescriptions — more than 67% of them.
Utilization by Glyburide product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
glyburide 5 MG Oral Tablet Most dispensed
Summed across the 11 of 158 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310537
glyburide 2.5 MG Oral Tablet
Summed across the 8 of 88 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310534
glyburide 1.25 MG Oral Tablet
Summed across the 4 of 40 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 197737
glyburide 6 MG Oral Tablet
Summed across the 1 of 10 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310539
glyburide 3 MG Oral Tablet
Summed across the 1 of 11 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 310536
glyburide 1.5 MG Oral Tablet
Summed across the 1 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 314000
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Glyburide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 26 of 313 listed Glyburide NDCs with Medicaid activity.
Compare Glyburide products
A representative set of FDA-listed product records for Glyburide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Tablet | ||||
| 2.5 mg | Oral | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | A-S Medication Solutions × 4 listings | ANDA | View NDC → |
| 2.5 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 5 mg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 1.25 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 2.5 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 5 mg | Oral | Cadila Pharmaceuticals Limited | ANDA | View NDC → |
| 1.25 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 2.5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 5 mg | Oral | Chartwell RX, LLC | ANDA | View NDC → |
| 2.5 mg | Oral | Coupler LLC | ANDA | View NDC → |
| 1.25 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | ANDA | View NDC → |
| 1.25 mg | Oral | Modavar Pharmaceuticals LLC | ANDA | View NDC → |
| 2.5 mg | Oral | Modavar Pharmaceuticals LLC | ANDA | View NDC → |
| 5 mg | Oral | Modavar Pharmaceuticals LLC | ANDA | View NDC → |
| 2.5 mg | Oral | Northwind Health Company, LLC | ANDA | View NDC → |
| 5 mg | Oral | Northwind Health Company, LLC | ANDA | View NDC → |
| 2.5 mg | Oral | NuCare Pharmaceuticals,Inc. | ANDA | View NDC → |
| 5 mg | Oral | NuCare Pharmaceuticals, Inc. × 3 listings | ANDA | View NDC → |
| 5 mg | Oral | NuCare Pharmaceuticals,Inc. × 4 listings | ANDA | View NDC → |
| 5 mg | Oral | Preferred Pharmaceuticals Inc. × 2 listings | ANDA | View NDC → |
| 2.5 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Proficient Rx LP × 2 listings | ANDA | View NDC → |
| 2.5 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 5 mg | Oral | Remedyrepack Inc. | ANDA | View NDC → |
| 1.25 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 1.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 3 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 6 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 1.25 mg | Oral | TEVA Pharmaceuticals USA Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 2.5 mg | Oral | TEVA Pharmaceuticals USA Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 5 mg | Oral | TEVA Pharmaceuticals USA Inc | NDA AUTHORIZED GENERIC | View NDC → |
| 1.25 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 2.5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 1.25 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | ANDA | View NDC → |
| 5 mg | Oral | Zydus Pharmaceuticals (USA) Inc. | ANDA | View NDC → |
Showing 55 of 55 products — FDA National Drug Code Directory. See every product, package size and price: browse all 55 Glyburide NDCs →
Glyburide side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Glyburide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Glyburide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Glyburide FDA approval history
How Glyburide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Glyburide recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Glyburide recalls since July 2021.
✅No Glyburide recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 4815 1 dose form · 9 strengths
-
Dose form (SCDF) Oral Tablet RxCUI 372333In current FDA listings
Look up RxCUI 4815 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Glyburide supply and shortage status
Whether Glyburide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Glyburide costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Tablet · Oral | 5 mg | $0.064 per tablet | NDC details & price history |
| Tablet · Oral | 2.5 mg | $0.063 per tablet | NDC details & price history |
| Tablet · Oral | 1.25 mg | $0.061 per tablet | NDC details & price history |
| Tablet · Oral | 1.5 mg | $0.160 per tablet | NDC details & price history |
| Tablet · Oral | 3 mg | $0.128 per tablet | NDC details & price history |
| Tablet · Oral | 6 mg | $0.239 per tablet | NDC details & price history |
| Tablet | 6 mg | $0.239 per tablet | NDC details & price history |
| Tablet | 3 mg | $0.128 per tablet | NDC details & price history |
| Tablet | 1.5 mg | $0.160 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Glyburide brand names
Glyburide is sold under 3 brand names in the FDA directory — DiaBeta, Glynase, Micronase. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Glyburide: manufacturers and labelers
15 companies list Glyburide products with the FDA. By number of product records, the largest are Teva Pharmaceuticals USA, Inc., NuCare Pharmaceuticals,Inc., A-S Medication Solutions. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Glyburide drug class (RxNorm)
Glyburide belongs to the Sulfonylurea class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Glyburide page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. TEVA Pharmaceuticals USA Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →